Mount Sinai IMPACC COVID-19 Cores

作为NIAID/DAIT计划的一部分，我们被选中参与一个多中心项目，即 COVID-19队列免疫表型评估（IMPACC），旨在收集和分配患者 样本和分析2000 COVID 19患者的免疫反应，使用特定的指定 丹在高影响COVID-19地区实施这一全国性免疫表型方案的主要目的是 进行详细的免疫表型分析和宿主因素的分析，这些因素可能预测或倾向于 感染消退与疾病进展及其后果。该协议旨在 告知疾病进展动力学和相关生物标志物;并进行详细的，纵向的 免疫分型（通过疾病进展表现），包括病毒载量的测量， 了解疾病进展中病毒载量和免疫病理学之间的相互作用。有一个 通过纳入所需的临床表征的所有方面，强调临床进展 将免疫发病机制与每个患者的每个疾病阶段相匹配。IMPACC以群组为基础， 由NAIAD/DAIT资助的人类临床中心开发的临床资源和技术 免疫学（CCHI）和人类免疫学项目联盟（HIPC）。因此，我们的团队一直 由于Fernando-Sesma博士目前是一个重债穷国中心的主要负责人， DHIPC研究人类对登革热、基孔肯雅病和寨卡病毒感染的免疫反应 Adeeb Rahman博士也是同一个重债穷国中心的重要成员， 免疫表型分析是该应用的核心领导者。此外，该团队的其他成员已被 根据他们在医院临床样本采集和处理方面的专业知识选择参与 分析呼吸道病毒感染反应的设置，包括病毒测序和病毒载量 测量.因此，这一对我们的母公司重债穷国赠款的行政补充，名为西奈山IMPACC， 在我们的母重债穷国基金的范围内，因为它专注于研究人类免疫反应， 病毒感染该应用程序的团队包括Viviana Simon博士，负责临床/样品 收集核心，阿德布拉赫曼博士，这将导致免疫异型核心，弗洛里安Krammer博士，领导 血清学核心，Harm货车Bakel博士，领导病毒测序核心以及Adolfo Garcia博士- Sastre作为合作研究者，Jaime Hook博士作为临床肺科医生。有了这个团队和 临床样本的可用性和适当的资源以及我们研究中心的生物防护，我们准备 提供样本并分析不同的免疫和病毒参数， 在COVID 19大流行期间的疾病严重程度和进展。西奈山医院位于纽约 约克市是美国这场大流行病的中心，已经在治疗数百名新冠肺炎患者。 患者

As part of an NIAID/DAIT initiative we have been selected to participate in a multicenter project, namely Immunophenotyping assessment in a COVID-19 Cohort (IMPACC), aimed to collect and distribute patient samples and to and analyze the immune responses of 2000 COVID19 patients using specific designated cores. The main purpose of this nationwide immunophenotyping protocol in high impact COVID-19 areas is to perform detailed immunophenotyping and analysis of the host factors that may predict or predispose to resolution of infection versus disease progression and its consequences. The protocol has been designed to inform disease progression dynamics and related biomarkers; and conduct detailed, longitudinal immunophenotyping (presentation through disease progression) that includes measures of viral load to understand the interplay between viral load and immune pathology in disease progression. There is an emphasis on the clinical progression by including all aspects of clinical characterization that will be needed to match immunopathogenesis with each disease stage within each patient. IMPACC builds on the cohorts and clinical resources and technology developed by the NAIAD/DAIT funded Clinical centers for Human Immunology (CCHI) and the Human Immunology Project Consortia (HIPC). Thus, our team has been selected by DAIT to participate, since Dr. Fernandez-Sesma is currently the PI of one of the HIPC centers, named DHIPC, which studies human immune responses to dengue, chikungunya and Zika virus infection and vaccination and Dr. Adeeb Rahman is also a crucial member of the same HIPC center and will be the Immonophenotyping core leader for this application. Additionally, other members of the team have been selected to participate based on their expertise in clinical sample collection and processing in hospital settings to analyze responses to respiratory viral infections, including viral sequencing and viral load measurement. Thus, this administrative supplement to our parent HIPC grant, named Mt Sinai IMPACC is within the scope of our parent HIPC award, since it is focused on the study of human immune responses to a viral infection. The team gathered for this application includes Dr. Viviana Simon, leading the clinical/sample collection core, Dr. Adeb Rahman, that will lead the immunopheotyping core, Dr. Florian Krammer, leading the serology Core, Dr. Harm Van Bakel, leading the virus sequencing core as well as Dr. Adolfo Garcia- Sastre as a co-investigator and Dr. Jaime Hook as a pulmonologist in the clinic. With this team and the availability of clinical samples and the appropriate resources and biocontainment at our site we are poised to provide samples and to analyze the different immune and viral parameters that will help us understand disease severity and progression in during the COVID19 pandemic. Mount Sinai Hospital is located in New York City, which is at the epicenter of this pandemic in the US and is already treating hundreds of COVID patients.